ErbB4-targeting monoclonal antibody(YUMAB)

N/A

Report date: 2023/01/09 16:01:37

Base Information

Drug NameErbB4-targeting monoclonal antibody(YUMAB)

Drug Alias NameN/A

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody

Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsT lymphocytes stimulantsReceptor protein-tyrosine kinase erbB-4 antagonists

TargetsReceptor protein-tyrosine kinase erbB-4

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryGermany

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesYumab GmbH

China Registration ClassN/A

Develop Information

Active CompaniesYumab GmbH

Inactive CompaniesN/A

Active IndicationsNeoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A